Andy joined J A Kemp from university 25 years ago. Since then, his patent practice has concentrated on global representation of UK universities and their spinouts and commercial partners in life science fields and European Patent Office (EPO) prosecution and opposition/appeal work. Clients range from early-stage businesses through top-tier UK and foreign academic institutions to one of one of the USA's most successful biopharmaceutical companies of recent times and one of the world's largest agriculture companies.
With a first class Cambridge degree in plant sciences, Andy has a particular interest in plant biotechnology, plant breeding and agri-tech and is available to advise on Plant Variety Right issues as well as patents across the agricultural sector, in which he has experience in areas including genetically modified crops, production of biopharmaceuticals in plant cell culture, breeding of crop and ornamental varieties, harvesting and crop production systems and tools for the automation of plant science research. He has a deep understanding of the complex considerations that surround patenting plants in Europe in light of the exclusion from patentability of plant varieties and essentially biological processes for the production of plants.
Building on this experience in agriculture, Andy is also active in industrial biotech work relating to microbial carbon capture and biofuel production. More recently, as gene therapy at last begins to deliver on its great potential, Andy has also become involved in several projects relating to viral delivery of treatments for ocular diseases and rare but debilitating inherited conditions that are hard to address in other ways.
Andy's other current major focus relates to antibody therapeutics and technology, where he is responsible for prosecution and EPO opposition work relating to multiple antibody and other biopharmaceutical products that are on or nearing the market and for a large portfolio of applications and oppositions relating to transgenic animal platforms for antibody drug discovery and antibody production methodology. This area has become increasingly contentious and Andy has therefore been involved in many EPO Oppositions and a number of items of UK and foreign litigation during the course of his career.
Representative examples of EPO Oppositions in which Andy has been involved at EPO Board of Appeal level include T400/97 relating to early techniques for recombinant antibody production; T188/97, T748/01 and T197/02 regarding HCV diagnostics; T857/01 and T1023/02 relating to HSV vaccines and gene therapy vectors; T202/02 concerning treatment of Crohns' disease; T1219/03 and T1919/11 on taxane production in plant cell culture; T94/04 relating to ligand trap cytokine antagonists; T67/05 regarding tetanus vaccines; T1108/08 relating to plant gene silencing; T2101/09 and T1153/14 concerning antibodies to Delta-4 and Nerve Growth Factor proteins respectively; and T1526/11 and T2220/14 relating to transgenic mouse platforms for antibody discovery.
Within J A Kemp, Andy leads the firm's US Business Development Group and has responsibility for the firm's relationships in Canada and Israel.
Andy joined J A Kemp in 1993, became a partner in 2003 and is the head of J A Kemp's fast-growing Cambridge office.
University of Cambridge, Masters Degree in Natural Sciences (Plant Sciences)
European Patent Attorney; UK Chartered Patent Attorney
Fellow of the Chartered Institute of Patent Attorneys (CIPA); Member of the Institute of Professional Representatives before the European Patent Office (EPI); Member of the International Federation of Intellectual Property Attorneys (FICPI)